Santhera drug approved in Europe for rare blindness disease

09/15/2015 // JusticeNewsFlash // (press release)

Switzerland – A new drug manufactured by Santhera Pharmaceuticals has been approved by European regulators for the treatment of a rare blindness disease. As reported by TheStreet, Raxone is the first to receive approval for treating Leber hereditary optic neuropathy (LHON).

The disease causes the progressive loss of vision and blindness in patients. An estimated 10,000 patients in Europe are affected by the disease for treating LHON, which is a defect in the mitochondrial DNA.

Santhera CEO Thomas Meier has said that the commercial launch of Raxone will begin in the coming weeks, but did not provide details about how the drug will be priced only saying it will be “priced as a typical orphan disease drug.”

The Raxone pill is designed to stimulate the organelles that produce energy that are found inside of cells, the mitochondria.

Read more about pharmaceutical lawsuits on Justice News Flash follow our Pharmaceutical Lawsuits News

More stories related to Pharmaceutical /?s=Pharmaceutical+

Source: The Street News Story

Media Information:

Phone: 866-598-1315